Anaconda Biomed Secures €20 Million Funding to Advance Next-Generation Thrombectomy System for Ischemic Stroke Treatment

VCBeat (WeChat ID: vcbeat) learned from foreign media reports that on December 4, 2019, U.S. medical device company Anaconda Biomed secured €20 million in new financing. The round was led by the prominent Barcelona-based venture capital firm Asabys Partners, with participation from Ysios Capital, Omega Funds, Innogest Capital, and Sabadell Venture Capital.

Anaconda Biomed, founded in 2015, is a Spanish medical technology company. The company is dedicated to developing next-generation thrombectomy systems for the treatment of ischemic stroke, with its flagship product being the Advanced Thrombectomy System.

The Anaconda Advanced Thrombectomy System consists of a delivery catheter, a funnel-shaped balloon catheter, and a stent retriever. During use by healthcare professionals, the balloon catheter automatically expands to match the arterial diameter (up to 5 mm), locally occluding blood flow to enable complete thrombus extraction without intravascular fragmentation.

Developing new and more effective therapies for stroke patients is a key focus of concern within the healthcare industry. According to The Lancet, stroke is the second leading cause of death worldwide. In 2016, 5.5 million people globally died from stroke. The Global Burden of Disease (GBD) 2016 report, published in The New England Journal of Medicine, indicated that the lifetime risk of stroke among individuals aged 25 years and older was 24.9% in 2016, an increase from 22.8% in 1990.

Regarding this financing round, Josep Ll, Co-founder of Asabys Partners, stated: “This investment in Anaconda aligns with our existing investment strategy, which focuses on pushing the boundaries of science and technology to address some of the most challenging medical issues.”

Sylvain Sachot, Investment Director at Asabys Partners, added, “We believe Anaconda will bring the most advanced thrombectomy system to the market for the effective treatment of ischemic stroke.”

Asabys Partners, a venture capital firm based in Barcelona, was established in 2018 and commenced operations in 2019. The firm focuses on medical technology, digital therapeutics, and early-stage biopharmaceuticals, supporting highly innovative and transformative technologies. Since its inception, Asabys Partners has invested in digital health companies Psious and Care Care, as well as the biotechnology company Ona Therapeutics.

Omega Funds is a global life sciences-focused investment firm founded in 2004 and headquartered in Boston, Massachusetts, USA. The company primarily provides funding to companies that leverage novel therapies, devices, or technology platforms to address serious unmet medical needs. Since its inception, the firm has raised over $700 million in capital.

(Compiled by Wang Fang)